Just five years ago, the world of variant interpretation was very different. There was no standard terminology for variant classification, and laboratories were using many different terms as ambiguous as "mutation" and "polymorphism" to convey pathogenicity, or lack thereof, and a plethora of qualifiers such as "possibly," "probably," and "likely" to convey degrees of uncertainty. The only terminology broadly agreed on was "variant of uncertain significance" (VUS). Furthermore, there was substantial variability in how laboratories evaluated evidence. A single publication in a peer-reviewed journal could be cited as justification for declaring pathogenicity, even though on many occasions little evidence to support that assertion was present in the publication beyond, for example, a non-statistically-significant observation in an affected individual. This was perpetuated by the routine deposition of "deleterious mutations" in the Human Gene Mutation Database, 1 often without strong evidence supporting these claims. Similarly, exemplar variants included in the Online Mendelian Inheritance in Man database 2 to support gene-disease relationships were assumed to be pathogenic.
EVOLVING STANDARDS FOR VARIANT INTERPRETATION
To address these issues, guidance was published in 2015 by the American College of Medical Genetics and Genomics (ACMG) and the Association of Molecular Pathology (AMP) to provide more detailed standards for how to weigh specific types of evidence and combine them to reach a classification for variants in Mendelian disease genes. 3 Standardized terms were also published: pathogenic, likely pathogenic, uncertain significance, likely benign, and benign. These guidelines have now been widely adopted by laboratories both nationally and internationally. While the development of detailed standards has brought greater consistency to variant classification, there remains both a degree of expert judgment and a learning curve in the accurate application of these guidelines. 4 The authors of the ACMG-AMP guidelines recognized this and acknowledged that the 2015 guidelines were a first step towards the goal of more objectively defining pathogenicity. An assumption was that these rules would see both general improvements as well as specific details added for individual genes and diseases over time. 3 In this month's issue of Genetics in Medicine, Nykamp et al. 5 report on a detailed evolution of the ACMG-AMP guidelines, transitioning to a semiquantitative framework with the use of a point-based scoring system and decision tree matrices. The ACMG-AMP committee had not decided to pursue a point-based system at the time over concerns that assigning points might lead to a false assumption of the quantitative accuracy of the approach, given substantial reliance on professional opinion to assign and weight certain types of evidence. However, it was recognized that a semiquantitative approach would improve the ability to combine both pathogenic and benign evidence, as well as to allow more gradation in the relative strength of each type of evidence. The careful approach taken by Nykamp et al. 5 to systematically dissect the evidence types presented in the guideline, as well as account for many additional subtleties in the types of evidence encountered in variant classification, should be commended. I anticipate that ClinGen's Sequence Variant Interpretation working group will carefully consider this approach as it works to provide additional guidance to the application of the ACMG-AMP guidelines and supports the ongoing evolution of this field.
As a testament to the utility of a standardized approach to variant classification, reported in this same issue of GIM, Harrison et al. 6 were able to show the successful resolution of 87% of interpretation differences among four major clinical laboratory submitters to ClinVar, with the majority of variants resolved through application of the ACMG-AMP guideline for variant interpretation. A similar rate of success was previously published with an analysis between two laboratories. 7 In an additional paper in this issue of GIM, Lebo et al. 8 examine variant interpretation among laboratories in the Canadian Open Genetics Repository and report on a consensus-driven process to variant curation through data sharing and application of the ACMG-AMP guidelines. In this study, the utility of data sharing through the Canadian Open Genetics Repository was demonstrated using BRCA1 and BRCA2 variant classifications from 11 diagnostic laboratories across Canada as a proof of principle. Using a three-tier model, discordant rates were reduced from 27% to 1 14%, with only 0.9% medically significant discordance after consensus efforts.
DEVELOPING A COMMUNITY-CENTRIC APPROACH TO VARIANT INTERPRETATION
In addition to the challenges in standardizing variant interpretation, another barrier arose over the past ten years. Laboratories were having difficulty keeping pace with the resources and expertise required to interpret the millions of variants being identified through high-throughput sequencing. It became clear that the most efficient mechanism for solving the problem was crowd sourcing. 9 If each laboratory shared its work in relation to gathering evidence and classifying variants, every laboratory would benefit. Most importantly, very few data from clinical laboratory testing were routinely published, preventing access to a large and important body of data. After a few attempts to solve this problem, a group of laboratories turned to the National Center for Biotechnology Information (NCBI) to consider launching a database of shared variant interpretations, which is now called ClinVar. 10 In parallel, these laboratories banded together through a National Institutes of Health U41 Genomic Resources grant (now part of ClinGen) to support data collection, standardization, and community sharing through a partnership with ClinVar. This effort was in part modeled on the successful International Standards for Cytogenomic Arrays Consortium, which brought cytogenetic laboratories together after the disruptive technology launch of cytogenomic microarrays into mainstream clinical genetics. 11 Not surprisingly, when laboratories began sharing data in ClinVar, the differences in variant interpretation methods that had been used over the past ten years became clear, as evidenced by the discordant variant interpretation records in ClinVar. 12 However, highlighting these differences through a "share and compare" approach allowed laboratories to resolve differences. In the study by Harrison et al., 6 the sharing of unpublished evidence helped resolve differences for 30% of variants. For some variants, the aggregate evidence from multiple laboratories moved variants from a classification of uncertain to either pathogenic or benign.
IS THE GLASS HALF FULL OR HALF EMPTY?
In assessments of ClinVar, two conflicting arguments have been made. One argument discredits ClinVar, arguing that the discordance observed makes the database untrustworthy and a risk to the community. 13, 14 The other view highlights ClinVar as a tremendous asset, allowing laboratories to share curated evidence used in interpretation, to identify discordant interpretations so they can be resolved, and to stimulate research on variants classified as being of uncertain significance. 12, [15] [16] [17] While I am inherently biased in my views as a funded ClinGen investigator who has also worked closely with the NCBI to guide the development of ClinVar, I think the rapid growth and usage statistics for ClinVar, and the absence of any documented harm whatsoever, bring an objective view that the database has become an invaluable positive asset.
That said, we have more work to do. In this issue of GIM, Yang et al. 17 report a detailed analysis of the data in ClinVar and note that ClinVar submissions from non-clinical laboratory sources (of which there are many) are far more likely to cause interpretation discrepancies than submissions from clinical laboratories, which are generally concordant. In addition, older submissions tend to disagree with newer ones, and low-penetrance variants (which usually have limited medical management implications) have more disagreement than high-penetrance ones. These factors appear to play a substantial role in the published comparisons that show high discordance among ClinVar entries. 13, 14, 18 Comparisons that carefully take such obvious factors into account show substantially higher concordance. 16, 17, 19, 20 The same factors could affect any ClinVar user. When ClinVar was launched, a star system was developed to distinguish the level of review that each variant had undergone, with the goal of aiding users in determining the trustworthiness of the variant interpretations in ClinVar. 12 Unfortunately, while the distinction between 0/1/2 stars (single laboratory submitters with (1 star) or without (0 star) interpretation criteria provided and all interpretations concordant (2 star)) versus 3/4 stars (ClinGen-approved expert panels (3 star) and professional guidelines (4 star)) is apparent, the distinction between 0-and 1-star submitters has been less clear, with a wider range of quality present, as demonstrated by Yang et al. 17 To ameliorate this problem, both Yang et al. 17 and ClinGen investigators have proposed alternatives to the representation of data in ClinVar. However, while the staff at the NCBI conduct an enormous effort to ensure the accurate and standardized representation of each variant and the submitted interpretations, ClinVar is an archive and does not itself pass judgment on the accuracy of the interpretations. As such, ClinGen is now pursuing alternative representation of ClinVar data that will support a more nuanced assignment of single-star submitter status, as well as a more facile ability to flag and remove old, outlier, and incorrect interpretations.
A CALL TO ACTION
As a clinical laboratory director of 15 years, I have seen a broad array of quality in molecular diagnostic laboratories. In my own anecdotal experience, I am now seeing a strong correlation between the quality of interpretations and whether the laboratory is a ClinVar submitter. I have also personally watched laboratories dramatically improve their interpretation methods after engaging in active data sharing in ClinVar. I therefore put out a plea to the community to step up and take action to ensure transparency in variant interpretation, to allow laboratories to subject their interpretations to peer review by the community, and to enable aggregation of evidence to improve knowledge over time. Various stakeholders can help as follows. 
THE END GOAL
As we continue to explore the best approaches to data sharing and representation of variant evidence, it is important to keep the end goal of variant interpretation in mind, which is to advance medicine and improve patient care. We must recognize that, similar to the rest of the practice of medicine, we will never be completely concordant in our interpretations of variants, which will inevitably continue to rely in part on professional opinion and evolving evidence. Nevertheless, we must ensure that the professional opinion of geneticists is based on a fully shared body of evidence with open and ongoing community review, and that we support this endeavor in a costeffective manner. A colleague once told me that the airline industry does not compete on safety because safety in flight is a fundamental right, highly regulated by federal law. Instead, the airlines focus on the added services they can provide to differentiate their businesses. It is time we considered the sharing of variant interpretations a fundamental right of patients to ensure that they receive accurate clinical care. Laboratories have plenty of other means to differentiate their services.
